Scarica l'app Stockscreener
44.94
1.83%
-0.84
Dopo l'orario di chiusura:
44.94
Precedente Chiudi:
$45.78
Aprire:
$45.8
Volume 24 ore:
309.17K
Relative Volume:
0.53
Capitalizzazione di mercato:
$1.24B
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-7.3914
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+1.33%
1M Prestazione:
+35.81%
6M Prestazione:
+91.97%
1 anno Prestazione:
+199.20%
Intervallo 1D:
$44.45
$46.81
Intervallo di 1 settimana:
$42.80
$47.86
Portata 52W:
$12.21
$47.86
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
44.94 | 1.27B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
JP Morgan maintains a sell rating on GSK plc (GSK) - MSN
683 Capital Management LLC Has $11.10 Million Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Camber Capital Management LP Sells 625,000 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio stock hits 52-week high at 46.57 USD - Investing.com
AnaptysBio stock hits 52-week high at 46.57 USD By Investing.com - Investing.com Australia
Stifel Nicolaus Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $56.00 - MarketBeat
AnaptysBio (ANAB) Analyst Rating Update: Stifel Lowers Price Target | ANAB Stock News - GuruFocus
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment - BioSpace
J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent - MSN
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighStill a Buy? - MarketBeat
Discipline and Rules-Based Execution in ANAB Response - news.stocktradersdaily.com
33,369 Shares in AnaptysBio, Inc. $ANAB Acquired by Panagora Asset Management Inc. - MarketBeat
AnaptysBio Files Legal Complaint Against GSK and Tesaro - MSN
AnaptysBio (ANAB): Assessing Valuation After Legal Battle Over Jemperli Royalties and Future Cash Flows Escalates - Sahm
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighHere's Why - MarketBeat
30,642 Shares in AnaptysBio, Inc. $ANAB Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Sells 27,809 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. stock deliver consistent dividendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser
AnaptysBio stock hits 52-week high at 43.35 USD - Investing.com
AnaptysBio stock hits 52-week high at 43.35 USD By Investing.com - Investing.com Nigeria
AnaptysBio Shares Navigate Legal Headwinds Amid Strong Performance - AD HOC NEWS
How institutional buying supports AnaptysBio Inc. stockMarket Performance Recap & Smart Money Movement Alerts - Newser
Why AnaptysBio Inc. (AN6) stock could break out in 2025Market Activity Recap & Real-Time Market Trend Scan - Newser
The Bull Case For AnaptysBio (ANAB) Could Change Following Jemperli Legal Clash With GSK Subsidiary - Yahoo Finance
Virtus Investment Advisers LLC Sells 6,909 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Jemperli Royalty Dispute Could Be a Game Changer for AnaptysBio (ANAB) - Sahm
Is AnaptysBio Inc. (AN6) stock a top hedge fund pickQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser
What sentiment indicators say about AnaptysBio Inc. stockPortfolio Return Report & Entry and Exit Point Strategies - Newser
ANAB: AnaptyBio Among Top Quality Stocks with High Returns - GuruFocus
AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says - marketscreener.com
A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus - simplywall.st
AnaptysBio Reports Q3 2025 Results and Strategic Plans - MSN
Why AnaptysBio Inc. stock could rally in 2025Portfolio Update Report & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
AnaptysBio FY2025 EPS Estimate Boosted by HC Wainwright - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26SEC filing - marketscreener.com
AnaptysBio files lawsuit against Tesaro and GSK over license deal - StreetInsider
AnaptysBio, Inc Files Lawsuit Against Tesaro and GSK - TradingView
Behavioral Patterns of ANAB and Institutional Flows - news.stocktradersdaily.com
What drives AnaptysBio Inc AN6 stock priceEconomic Data Impact & Rapid Portfolio Appreciation - earlytimes.in
Anaptys Announces Participation in December Investor Conferences - The Manila Times
AnaptysBio, Inc. to Participate in Upcoming Investor Conferences Featuring Leadership Team Insights - Quiver Quantitative
Wedbush Backs AnaptysBio As Buyback Eases Investor Fears - Finimize
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighHere's What Happened - MarketBeat
AnaptysBio's (ANAB) Outperform Rating Reiterated at Wedbush - MarketBeat
HC Wainwright Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
DCF Advisers LLC Purchases 13,150 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - Nasdaq
AnaptysBio stock hits 52-week high at 41.12 USD By Investing.com - Investing.com Nigeria
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Anaptysbio Inc Azioni (ANAB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):